Aragen Bioscience, a privately held CRO, and Innovent Biologics, a privately held biopharmaceutical company, have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Aragen Bioscience will develop robust CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics.
“Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products,” said Michael Yu, CEO of Innovent.
Aragen Bioscience focuses on customer service and technical leadership to enable clients to cost-effectively accelerate their research efforts. Aragen Bioscience offerscell line development, protein expression and purification, molecular biology, cell biology immunology and diverse in vivo services to the biotech and pharmaceutical industries.
“Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration,” said Oren Beske, Ph.D., vice president of Aragen Bioscience.